机器学习识别了基于免疫的生物标志物,这些生物标志物预测了在晚期肺癌中基于抗血管生成疗法的疗效
Peixin Chen1, Lei Cheng2, Chao Zhao2
1Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China; School of Medicine, Tongji University, Shanghai 2000922, China.
International immunopharmacology
|November 18, 2024
概括
整合治疗前循环的炎症生物标志物可以在接受抗血管性疗法的晚期肺癌患者中非侵入性预测临床结果. 这种基于免疫的模型预测了治疗反应和无进展生存率,有助于早期识别合适的候选人.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 数据科学数据科学数据科学
背景情况:
- 抗血管生成药物对肺癌有效,但预测患者的反应仍然具有挑战性.
- 瘤免疫细胞和外周血液标记物的作用在预测抗血管生成疗法的结果方面尚不清楚.
- 开发一个预测模型可以帮助识别那些将从这些疗法中受益最多的晚期肺癌患者.
研究的目的:
- 开发和验证基于机器学习的免疫预后模型,用于预测在接受基于抗血管生成治疗的晚期肺癌患者的临床结果.
- 确定关键的瘤内免疫细胞丰度和外围血液免疫特征,这些特征与治疗反应和无进展生存相关.
主要方法:
- 分析了接受基于抗血管生成的治疗的1058名III-IV期肺癌患者的现实世界队列.
- 用多重免疫光 (mIF) 对CD68和PD-L1.1等标记物的瘤免疫微环境进行了评估.
- 一个机器学习模型 (LightGBM) 使用系统性炎症指数,如中性粒细胞与淋巴细胞的比率 (NLR),单细胞与淋巴细胞的比率 (MLR) 和系统性炎症反应指数 (SIRI) 开发.
主要成果:
- 内CD68+巨细胞和循环炎症指数 (NLR,MLR,SIRI,M:L比率) 与药物反应和无进展生存时间 (PFS) 有意义地相关.
- 开发的非侵入性预测模型显示了治疗响应 (AUC:0.799) 和PFS (0.7006-0.915) 的高预测性能.
- 与其他群体相比,具有较高炎症标记的患者 (循环群3) 显示PFS明显更差.
结论:
- 在治疗前循环的炎症生物标志物可以有效而非侵入性地预测肺癌抗血管原治疗的临床结果.
- 开发的基于免疫的预后模型是评估系统性炎症和预测晚期肺癌患者预后的宝贵工具.
- 这种模型可以帮助早期识别可能受益于抗血管生成治疗的患者,优化治疗策略.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480


